Cancer-related sarcopenia is mainly characterized by protein degradation and muscle depletion caused by catabolism, leading to a decrease in the quality, strength, and function of skeletal muscles. Pancreatic cancer has the highest incidence of cancer-associated sarcopenia. More than 80% of pancreatic cancer patients have the Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, which promote the progress of sarcopenia. The authors systematically elaborate the interaction mechanism between KRAS-mutant pancreatic cancer and sarcopenia, mainly in four aspects: (1) KRAS driven metabolic reprogramming leads to depletion of muscle energy reserves, affecting the redistribution of muscle fiber energy and resulting in unidirectional energy flow for cancer cell proliferation. (2) By altering the cytokine profile, activating the ubiquitin protease system and the autophagy lysosome pathway, the cancer cells promote myotube degradation, inhibit muscle regeneration, disrupt muscle homeostasis, and lead to unidirectional flow of nutrients to support tumor growth. (3) Oxidative stress caused by cancer cells damages skeletal muscles. (4) Cancer cells induce immune cell remodeling in skeletal muscle. Meanwhile, the authors review the treatment progress of KRAS-mutant pancreatic cancer-related sarcopenia. With the deepening research of KRAS-mutant pancreatic cancer-related sarcopenia, targeted therapy and personalized intervention are expected to become important means to improve the prognosis and quality of life of patients.

Laparoscopic technology has become an important choice for ventral hernia repair due to its advantages of minimal trauma and rapid recovery. Traditional non-absorbable synthetic meshes are the most commonly used type of mesh in laparoscopic ventral hernia repair. Although they provide reliable mechanical support, their long-term presence in the human body may cause mesh erosion and wrinkling, leading to complications such as intestinal fistula, abdominal adhesions, postoperative foreign body sensation, chronic pain, and infection, which are receiving increasing attention. Absorbable meshes, with their excellent biocompatibility and ability to induce tissue remodelling, can reduce the incidence of the above complications and are revolutionising laparoscopic ventral hernia repair. The authors introduce the types and characteristics of existing absorbable mesh, focusing on their clinical efficacy in laparoscopic ventral hernia repair, existing challenges and countermeasures, as well as individualized surgical decision-making in laparoscopic ventral hernia repair.

Sleeve gastrectomy is currently the most commonly performed bariatric surgery procedure. There remains controversy regarding the intraoperative management of hiatal hernia during sleeve gastrectomy for obesity patients. In China, the mainstream approach is active explora-tion and repair of the hiatal hernia during surgery. Nevertheless, some reports suggest that this may not lead to definitive outcomes and might even exacerbate gastroesophageal reflux symptoms. Based on clinical experience, the authors discuss the current strategies of intraoperative management of hiatal hernia during sleeve gastrectomy, and explore the clinical management strategies for obesity patients with esophageal hiatal hernia undergoing sleeve gastrectomy.

The contents of the female inguinal hernia include abdominal organs such as ovaries and fallopian tubes, and most of these are the result of sliding hernias. However, it is worth noting for surgeons specialized in hernia and abdominal wall surgery that there is a rare clinical diagnosis of hernia uterine inguinale, which is commonly seen in the Müllerian anomaly. Combined with relevant research progress at home and abroad, as well as the clinical experience in the diagnosis and treatment of patients with inguinal uterine hernia caused by Müllerian duct anomaly, the authors systematically introduce the clinical manifes-tations, key diagnosis and treatment points of female Müllerian duct anomaly in the inguinal region.

Radical resection is the key for long-term survival of pancreatic cancer patients. The positive rate of arterial margin after pancreatic cancer surgery is still high, and the peri-arterial area is a high-risk area for local recurrence after surgery, suggesting that the arterial involvement of tumor is still a challenge in the surgical treatment of pancreatic cancer, and the corresponding surgical technical countermeasures have become a hot spot and focus in the field. The authors summarize the latest progress in research on surgical treatment for arterial involvement of pan-creatic cancer, generalize the experiences of peri-arterial dissection in two large pancreatic cancer centers in China and Japan, and give their perspectives to the future development of pancreatic surgery in this field.

Objective:To evaluate the prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated by gemcitabine and nab-paclitaxel (AG) or AG combined with pro-grammed death-1 (PD-1) inhibitor regimen and application value of the Cleveland Clinic Foundation (CCF) risk score.Methods:The retrospective cohort study was conducted. The clinicopathological data of 151 PDAC patients who were treated by AG regimen or AG combined with PD-1 inhibitor regimen in Zhejiang Cancer Hospital from January 2013 to March 2024 were collected. There were 84 males and 67 females, aged (64±9)years. Observation indicators: (1) comparison of clinical characteristics among resectable PDAC patients with different CCF risk score; (2) analysis of influencing factors for overall survival time of resectable PDAC patients; (3) survival of resectable PDAC patients. Comparison of measurement data with skewed distribution between groups was conducted using the Mann-Whitney U test. Comparison of count data between groups was conducted using the chi-square test. Comparison of ordinal data between groups was conducted using the rank sum test. Univariate and multivariate analyses were conducted using the Cox regression model. Kaplan-Meier method was used to calculate survival rate and plot survival curve, and Log-rank test was used for survival analysis. Results:(1) Comparison of clinical characteristics among resectable PDAC patients with different CCF risk score. Based on CCF risk score, 102 of 151 patients were classified as low risk and 49 cases were classified as intermediate-to-high risk. There were signi-ficant differences in sex, age, smoking status, alcohol consumption, hypertension, and diabetes between the two categories ( P<0.05). (2) Analysis of influencing factors for overall survival time of resectable PDAC patients. Results of multivariate analysis showed that the treatment regimen was an indepen-dent influencing factor for overall survival time of resectable PDAC patients ( hazard ratio=1.976, 95% confidence interval as 1.065?3.666, P<0.05). (3) Survival of resectable PDAC patients. The follow-up time of 151 patients was 21.8(18.7,24.2)months, and the median overall survival time was 23.3(19.0,32.4)months. The follow-up time was 22.1(18.9,30.7)months of patients treated by AG regimen and 11.2(8.1,23.3)months of patients treated by AG combined with PD-1 inhibitor regimen, respectively. The median overall survival time of the two types of patients was 24.4(17.2,31.7)months and 16.9(8.9,24.9)months. The 1-year overall survival rates were 79.1% and 60.0%, and the 2-year overall survival rates were 53.4% and 28.5%, respectively. There was a significant difference in the overall survival between the two types of patients ( hazard ratio=1.913, 95% confidence interval as 1.041?3.516, P<0.05). Of the intermediate-to-high risk patients, the follow-up time was 18.5(8.8,28.1)months of 37 patients treated by AG regimen and 8.1(7.3,9.0)months of 12 patients treated by AG combined with PD-1 inhibitor regimen. The median overall survival time of the two types of patients was 32.4(15.7,49.0)months and 8.9(5.7,12.1)months, respectively. The 1-year overall survival rates were 82.7% and 31.3%, and the 2-year overall survival rates were 66.5% and 0, respectively. There was a significant difference in the overall survival between the two types of patients ( hazard ratio=5.402, 95% confidence interval as 1.811?16.118, P<0.05). Conclusions:The treatment regimen is an independent influencing factor for overall survival in patients with resectable PDAC. Compared with the AG combined with PD-1 inhibitor regimen, AG regimen is associated with good survival of patients with resectable PDAC. For patients classified as intermediate-to-high risk based on the CCF risk score, AG regimen is assiociated with a better overall survival compared to AG combined with PD-1 inhibitor regimen.

Pancreaticoduodenectomy (PD) is a primary surgical approach for treating mali-gnant tumors of the pancreatic head and the periampullary region. With the advance in medical technology in recent years, the long-term survival rate of patients undergoing PD has significantly improved, and the incidence of early perioperative complications has markedly decreased. However, current researches predominantly focuse on early postoperative complications, while, limited studies addressing long-term complications. Long-term complications after PD have a significant impact on patients′ quality of life and long-term survival. This authors systematically summarize the common long-term complications following PD, and explore their mechanisms, clinical manifestations, dia-gnostic methods, and treatment strategies, aiming to provide a reference for clinical practice.

The surgical treatment of synchronous colorectal liver metastases (sCRLM) is complex, especially regarding the optimal strategy for resectable cases is controversy. The contro-versies exist in choosing between simultaneous and staged resection, the sequence of bowel-first or liver-first in staged resection, and the feasibility of laparoscopic surgery for liver metastases. Based on current situations of surgical treatment at home and abroad and clinical practice experience of the team, the authors compare the efficacy of simultaneous, bowel-first, and liver-first resection, and discuss the application of laparoscopic techniques in the treatment of liver metastases. Analysis indicates that the selection of surgical strategy according to liver metastasis burden can significantly improve the surgical safety and survival benefits: for solitary and unilobar multifocal metastases, the three strategies yield similar survival prognoses, yet simultaneous resection may elevate infection risks; for bilobar multifocal metastases, the liver-first approach shows lower total complications, infection, and mortality rates, and better long-term survival, making it preferable. In addition, strategy selection should also account for patient tolerance, surgical team skills, estimated operation time and risks. Laparoscopic surgery has advantages as minimal invasiveness, faster recovery, fewer complications, and equivalent long-term prognosis to open surgery. It should be the first-choice approach for both simultaneous and staged resection in the treatment of liver metastases.

The persistence of obesity is rooted in energy storage mechanisms formed through millions of years of evolution, combined with the systematic influence of the modern "obesogenic environment", constituting a complex regulatory network involving coordinated neural, endocrine, and metabolic systems. Current mainstream treatment methods exhibit significant limitations: glucagon-like peptide-1 receptor agonists demonstrate remarkable short-term weight loss effects but present issues with tolerance development and post-discontinuation weight regain; bariatric metabolic surgery similarly faces long-term weight recurrence challenges, with approximately one-third of patients experiencing weight regain within five years after surgery. Therefore, comprehen-sive obesity treatment must establish a new paradigmatic framework: utilizing cognitive behavioral intervention as the therapeutic foundation, employing multi-dimensional strategies including mindful eating training, nutritional management, and exercise intervention to help patients establish sustain-able lifestyle changes; repositioning pharmaceutical and surgical medical interventions as supportive measures for behavioral change; constructing multi-level social support environments encompassing policy, community, and family domains to achieve transformation from treatment goals focused solely on weight reduction to metabolic health improvement, from success definition based on short-term weight loss to long-term maintenance, and from medical-dominated treatment systems to patient-centered multidisciplinary collaborative approaches. Ultimately, through the deep integration of biomedical precision, patient cognitive initiative, and social support inclusiveness, a sustainable collaborative pathway for obesity treatment can be established. Based on twenty years of clinical experience in bariatric and metabolic surgery, the authors provide an in-depth analysis of the treat-ment challenges faced by obesity as a complex disease and proposes the necessity of transitioning from traditional single medical interventions to a biopsychosocial comprehensive treatment model.

The prevalence of obesity is continuously increasing worldwide, making it a major global health issue that impacts public health and places a growing burden on healthcare systems. Bariatric metabolic surgery, currently the most effective treatment for weight loss and improving obesity-related metabolic diseases, still has significant limitations in patient selection, personalized surgical planning, and accurate prediction of postoperative complications and weight loss outcomes. With the rapid advancement of artificial intelligence (AI) technology, the diagnostic and therapeutic paradigm of bariatric and metabolic surgery is expected to undergo revolutionary improvement. The authors explore the latest applications of AI in bariatric and metabolic surgery, including surgical training, preoperative diagnosis and formulation of treatment strategy, intra-operative assistance, as well as prediction of related risks and weight loss effects after surgery. It aims to provide valuable insights for clinical practice, facilitating the evolution of bariatric and metabolic surgery toward greater precision, efficiency, and personalization.